Annovis Bio, INC

Annovis Bio, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where all five proposals, including director elections and equity plan amendments, were approved.

Annovis Bio reports Q1 2026 financial results while highlighting significant enrollment progress in its Phase 3 Alzheimer's and Parkinson's clinical trials.

Annovis Bio, Inc. announced the departure of Chief Financial Officer Mark Guerin, with CEO Maria Maccecchini assuming the role on an interim basis.

Annovis Bio announced its fiscal year 2025 financial results and provided updates on its pivotal Phase 3 Alzheimer's disease study and open-label Parkinson's disease study.

Annovis Bio receives positive DSMB recommendation for buntanetap's safety, allowing its pivotal Phase 3 Alzheimer's disease trial to continue without modification.

Annovis Bio provided an update on its buntanetap clinical programs for Alzheimer's and Parkinson's diseases, detailing progress in pivotal Phase 3 AD enrollment and the initiation of a Parkinson's Open Label Extension study.

Annovis Bio reports a net loss of $17.6 million for Q1 2026 as it advances its lead neurodegeneration candidate, buntanetap, through pivotal clinical trials.

Annovis Bio reported increased net losses and cash burn for Q3 2025, raising substantial doubt about its ability to continue as a going concern, despite positive clinical trial data and recent capital raises.

Annovis Bio, a clinical-stage biopharmaceutical company, reported increased net losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern despite progress in its neurodegeneration drug trials.

Annovis Bio reports its Q1 2025 financial results, highlighting ongoing clinical trials and recent FDA interactions.

Annovis Bio's Q3 2024 report details a net loss of $12.6 million, a decrease in research and development expenses, and updates on their clinical trials for Alzheimer's and Parkinson's disease.

Annovis Bio's Q2 2024 report highlights continued clinical trial progress for Buntanetap, alongside a net loss and ongoing efforts to secure additional funding.

Annovis Bio reports progress in its pivotal Phase 3 Alzheimer's and Open-Label Extension Parkinson's trials for buntanetap, while acknowledging substantial doubt about its ability to continue as a going concern without additional financing.

Annovis Bio reports positive clinical trial results for buntanetap in treating neurodegenerative diseases but acknowledges substantial doubt about its ability to continue as a going concern due to recurring losses.

Annovis Bio's 10-K filing outlines the company's capital structure, including common and preferred stock details, registration rights, and anti-takeover provisions.

Annovis Bio director Michael Hoffman acquired 76,344 shares of common stock through open market purchases.

Michael B. Hoffman, a Director at Annovis Bio, Inc., acquired 713,800 shares of common stock on April 2, 2026.

Annovis Bio Director Michael B Hoffman acquired 45,000 shares of common stock for approximately $190,000, signaling confidence in the company.

Annovis Bio Director Michael B. Hoffman filed an amended Form 4 to correct reported beneficial ownership totals following multiple common stock purchases.

Annovis Bio, Inc. Director Michael B. Hoffman acquired 39,200 shares of common stock for approximately $159,875 on November 24, 2025.

Annovis Bio, Inc. Director and 10% owner Michael B. Hoffman acquired 20,000 shares of common stock for approximately $70,000 through open market purchases.

Annovis Bio, Inc. has issued its 2026 proxy statement detailing director elections, auditor ratification, and proposed equity plan amendments.

Annovis Bio, Inc. will hold its annual stockholders meeting virtually on June 17, 2025, to elect directors and ratify the selection of Ernst & Young LLP as its independent accounting firm.

Annovis Bio, Inc. has scheduled its 2025 Annual Meeting of Stockholders for June 17, 2025, to be held virtually.

Annovis Bio's CEO, Maria Maccecchini, issued a letter to stockholders addressing concerns and outlining next steps following the Phase II/III Alzheimer's study results.

Annovis Bio, Inc. will hold its annual meeting of stockholders virtually on June 12, 2024, to vote on the election of directors, an amendment to the equity incentive plan, and the ratification of Ernst & Young LLP as the independent accounting firm.

Annovis Bio is holding its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to vote on director elections, an amendment to the 2019 Equity Incentive Plan, and ratification of Ernst & Young LLP as the independent auditor.

Empery Asset Management, LP and Ryan M. Lane report a 5.64% stake in Annovis Bio, Inc. as of June 30, 2026.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a 4.9% beneficial ownership stake in Annovis Bio, Inc., primarily through warrants, as detailed in an amended Schedule 13G filing.

CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc., have disclosed a passive beneficial ownership of 5.1% in Annovis Bio, Inc., totaling 1,000,000 shares of common stock.